The Evolution of The ctDNA Assays – From Initial Clinical & Regulatory Utility to a Potential Innovative MRD Endpoint in Solid Tumor Indications • Clinical and regulatory utility of first generation
- Clinical and regulatory utility of first generation ctDNA assays
- The need for innovative endpoints and important advancements of ctDNA assays to serve as MRD assays
- An example of a potential pathway to establish ctDNA for MRD testing in a solid tumor indication